Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation
Abstract Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus. Elimination of these reservoirs through th...
Guardado en:
Autores principales: | Brice J. Albert, Austin Niu, Rashmi Ramani, Garland R. Marshall, Paul A. Wender, Robert M. Williams, Lee Ratner, Alexander B. Barnes, George B. Kyei |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/51c1c2571b74471db5299a641c3986a0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Developmental Toxicology of Metal Mixtures in <i>Drosophila</i>: Unique Properties of Potency and Interactions of Mercury Isoforms
por: Catherine R. Beamish, et al.
Publicado: (2021) -
Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Madhumanti Barman, et al.
Publicado: (2021) -
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: María Rosa López-Huertas, et al.
Publicado: (2017) -
High-potency ligands for DREADD imaging and activation in rodents and monkeys
por: Jordi Bonaventura, et al.
Publicado: (2019) -
Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency
por: George B. Kyei, et al.
Publicado: (2018)